Health ❯ Healthcare ❯ Clinical Trials

Phase 3 Trials

Efficacy Studies Eli Lilly Trials Drug Efficacy C-POST Trial Efficacy and Safety Eli Lilly Lecanemab DESTINY-Breast09 Trial BREAKWATER Trial Weight Loss Medications

4 ARTICLES

last wk.

Roche Stops Phase 3 for Acmopatide After Positive Phase 2 in Type 1 Diabetes

The move pauses development of a once‑daily GLP‑1/GIP dual agonist after a 16‑week trial showed A1C reductions, meaningful weight loss, and lower insulin needs.

3 ARTICLES

last wk.

FDA Approves Xocova as First Oral Post-Exposure COVID-19 Prophylaxis

4 ARTICLES

2w ago

EU Panel Recommends Braftovi Plus Cetuximab and FOLFOX for First‑Line BRAF‑Mutant Colorectal Cancer

35 ARTICLES

3w ago

Lilly’s Triple‑Agonist Retatrutide Produces Surgery‑Level Weight Loss in Phase 3 Trial

3 ARTICLES

3w ago

EMA Recommends Etcamah for ESR1‑Mutant Advanced Breast Cancer

7 ARTICLES

3w ago

FDA Approves Baxfendy, First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension

3 ARTICLES

last mo.

Moderna’s mRNA Flu Shot Tops Standard Vaccine in Large Phase 3 Trial

13 ARTICLES

last mo.

FDA Panel Rejects AstraZeneca Breast Cancer Drug, Backs Prostate Therapy

6 ARTICLES

last mo.

FDA Clears Vepdegestrant, First PROTAC Cancer Drug, for ESR1‑Mutated Breast Cancer

6 ARTICLES

last mo.

Boehringer’s Dual-Agonist Survodutide Cuts Body Weight by Up to 16.6% in Phase III Trial

4 ARTICLES

last mo.

FDA Clears Once-Weekly Saphnelo Pen for Self-Injection in Lupus

3 ARTICLES

last mo.

EMA Panel Recommends Redemplo for Familial Chylomicronaemia Syndrome

5 ARTICLES

last mo.

EMA Validates Astellas Bid to Add Padcev–Keytruda Combo for Perioperative Muscle-Invasive Bladder Cancer

3 ARTICLES

last mo.

Xenon Presents Phase 3 Azetukalner Results and 48‑Month Data at American Academy of Neurology Meeting

19 ARTICLES

2mo ago

Revolution Medicines Drug Nearly Doubles Survival in Phase 3 Pancreatic Cancer Trial

9 ARTICLES

2mo ago

FDA Approves Filspari to Reduce Proteinuria in FSGS Patients Without Nephrotic Syndrome

8 ARTICLES

2mo ago

Evolocumab Cuts First Cardiovascular Events by 31% in High‑Risk Diabetes Without Known Atherosclerosis

20 ARTICLES

2mo ago

Pfizer, Valneva Seek Approval for Lyme Vaccine After >70% Efficacy in Phase 3

3 ARTICLES

2mo ago

Pfizer–Valneva Lyme Vaccine Shows Over 70% Efficacy but Misses Primary Endpoint

5 ARTICLES

2mo ago

FDA Approves First Therapy for Acquired Hypothalamic Obesity, Expanding Rhythm’s Imcivree

Phase 3 Trials

Roche Stops Phase 3 for Acmopatide After Positive Phase 2 in Type 1 Diabetes

FDA Approves Xocova as First Oral Post-Exposure COVID-19 Prophylaxis

EU Panel Recommends Braftovi Plus Cetuximab and FOLFOX for First‑Line BRAF‑Mutant Colorectal Cancer

Lilly’s Triple‑Agonist Retatrutide Produces Surgery‑Level Weight Loss in Phase 3 Trial

EMA Recommends Etcamah for ESR1‑Mutant Advanced Breast Cancer

FDA Approves Baxfendy, First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension

Moderna’s mRNA Flu Shot Tops Standard Vaccine in Large Phase 3 Trial

FDA Panel Rejects AstraZeneca Breast Cancer Drug, Backs Prostate Therapy

FDA Clears Vepdegestrant, First PROTAC Cancer Drug, for ESR1‑Mutated Breast Cancer

Boehringer’s Dual-Agonist Survodutide Cuts Body Weight by Up to 16.6% in Phase III Trial

Never miss stories about

Phase 3 Trials

FDA Clears Once-Weekly Saphnelo Pen for Self-Injection in Lupus

EMA Panel Recommends Redemplo for Familial Chylomicronaemia Syndrome

EMA Validates Astellas Bid to Add Padcev–Keytruda Combo for Perioperative Muscle-Invasive Bladder Cancer

Xenon Presents Phase 3 Azetukalner Results and 48‑Month Data at American Academy of Neurology Meeting

Revolution Medicines Drug Nearly Doubles Survival in Phase 3 Pancreatic Cancer Trial

FDA Approves Filspari to Reduce Proteinuria in FSGS Patients Without Nephrotic Syndrome

Evolocumab Cuts First Cardiovascular Events by 31% in High‑Risk Diabetes Without Known Atherosclerosis

Pfizer, Valneva Seek Approval for Lyme Vaccine After >70% Efficacy in Phase 3

Pfizer–Valneva Lyme Vaccine Shows Over 70% Efficacy but Misses Primary Endpoint

FDA Approves First Therapy for Acquired Hypothalamic Obesity, Expanding Rhythm’s Imcivree

Never miss stories about

Phase 3 Trials